RA – Rheumatoid Arthritis is one of the most common chronic autoimmune diseases that causes inflamed joint lining and erosion of the cartilage and bone. According to the Center for Disease Control and Prevention, it is estimated that 1.5 million adults are affected by RA within the United States.
What hUC-MSC can do is to modulate innate and adaptive immune cells by inducing peripheral tolerance by increasing regulatory T cells and blocking activated T cells proliferation. hUC-MSC also can migrate towards injured tissues to suppress proinflammtory cytokines and directly or indirectly facilitate the repair and regeneration of the damaged joints.
Current RA Treatment Challenges
Rather than a real cure, current RA treatment can only temporarily alleviate symptoms while often bring in moderate to severe side effects. Most patients eventually lose responses from their periodic completion of treatment.
The RA treatment has undergone progression from early traditional therapies (Conventional DMARDs such as methotrexate, sulfasalazine) to Biologic Therapies (Biologic DMARDs such as TNF-α antagonist, IL-1R antagonist). Our product BX-U001 represents the groundbreaking novel therapies in the hUC-MSC research and clinical field as an industry-leading pioneer.
Supportive Evidence of hUC-MSC treatment for RA